Resuming Normal Drug and Biologics Manufacturing Operations During the COVID-19 Public Health Emergency: Guidance for Industry | NLM

Disaster Information Management Research Center | NLM

Resuming Normal Drug and Biologics Manufacturing Operations During the COVID-19 Public Health Emergency: Guidance for Industry

09/01/2020 12:00 AM EDT

Source: U.S. Food and Drug Administration (FDA). Published: 9/2020. The FDA is issuing this 12-page guidance to help drug and biological product manufacturers during the COVID-19 public health emergency plan and prioritize current good manufacturing practice (CGMP) activities as they transition from operations impacted by the public health emergency to normal manufacturing operations. (PDF)